Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab–irinotecan in children with low‐grade glioma?

The association of bevacizumab and irinotecan has been shown to display a quick efficacy in low‐grade glioma (LGG), but most patients relapse within months after cessation of therapy. From October 2012 to March 2014, four patients have been treated with irinotecan–bevacizumab followed by a metronomi...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer Med
Huvudupphovsmän: Heng, Marie Amélie, Padovani, Laetitia, Dory‐Lautrec, Philippe, Gentet, Jean Claude, Verschuur, Arnaud, Pasquier, Eddy, Figarella‐Branger, Dominique, Scavarda, Didier, André, Nicolas
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2016
Ämnen:
Clinical Cancer Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4944881/
https://ncbi.nlm.nih.gov/pubmed/27037940
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.699
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk